A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Tobramycin (Primary)
- Indications Bronchiectasis
- Focus Therapeutic Use
- Acronyms iBEST-1
- Sponsors Novartis
- 26 Apr 2017 Planned End Date changed from 19 Jun 2018 to 10 Sep 2018.
- 26 Apr 2017 Planned primary completion date changed from 19 Jun 2018 to 10 Sep 2018.
- 14 Feb 2017 Planned End Date changed from 1 May 2018 to 19 Jun 2018.